{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The cardiac monitoring was measured by using an appropriate nonimplantable recording device which is acceptable to the participants. This was evaluated the arrhythmic background of eligible cardiac amyloidosis participants such that false positive attribution of arrhythmias to GSK3039294 during repeat dosing was minimized.","groups":[{"description":"Participants received GSK3039294 600 mg, capsules, orally, under fed condition, QD for 7 days in cohort 3.","id":"OG000","title":"Part B: Cohort 3- GSK3039294 600 mg QD"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population.","reportingStatus":"POSTED","timeFrame":"Cohort 3: Up to Day 8","title":"Part B: Number of Participants With Abnormal Cardiac Telemetry Findings","type":"PRIMARY","unitOfMeasure":"Participants"}